Education & Training

 

AGA Education, Practice and Research

Focused Clincial Updates 2006

To receive full CME credit, you are required to complete the evaluation form and self-test for each chapter you complete. Upon completion of the evaluation form and test, a certificate with your name and number of credits you have claimed will be generated. You must print your certificate using the print function in your browser.

The objectives listed below are to be used when evaluating the program. After completing this program, each participant should be able to:

  • Identify how state of the art and emerging research will impact management of digestive conditions.
  • Review diagnostic and treatment options for patients with several digestive diseases.

 

Non-Alcoholic Fatty Liver Disease

Select one answer for each question. You may change your answers as many times as you need to until you click the "Submit" button located at the bottom of the test.

1.With regard to safety of statin drugs in patients with pre-existing liver disease:

Lovastatin was found to have a low prevalence of liver toxicity, similar to match controls not on the drug in a retrospective case-control study

Pravastatin and placebo showed similar results in ALT levels in a randomized, controlled, clinical trial

Both are correct

Neither are correct

2. Patients with non-alcoholic steatohepatitis treated with probucol for one year demontstrated:

An increase in ALT

A decrease in ALT

An improvement in histology

An improvement in NASH scores

3. Dehydroepiandrosterone (DHEA) levels in non-alcoholic fatty liver disease:

Patients with low DHEA levels had more severe fibrosis

Patients with low DHEA levels had less severe fibrosis

DHEA levels do not in any way predict the severity of fibrosis

DHEA levels are higher the older we are

4. Ultrasonic transient elastography (Firborscan®):

Is a non-invasive test to assess hepatic fibrosis

Appears to be a viable technique for detecting severe fibrosis in patients with NASH

Can be used to screen for hepatocellular cancer

A and B are correct